$
Federal Contract Award
Amgen USA INC
Department of Health and Human Services · March 6, 2026 · FY2026
75A50122C00065Full & OpenNAICS 541714
Obligated
$773,879,007
Contract details
- Award ID
- CONT_AWD_75A50122C00065_7505_-NONE-_-NONE-
- PIID
- 75A50122C00065
- Period of performance
- September 30, 2022 → September 29, 2032
- Place of performance
- NEWBURY PARK, CA, USA
- Set-aside
- None (Full & Open)
- Pricing type
- FIRM FIXED PRICE
- PSC
- AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- NAICS
- 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Scope
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.
Parent vehicle (IDV)
Amgen USA INC
UEI Y6NEW42XK544
This award was placed as a task/delivery order under a larger contract vehicle.
Awarding agency
Department of Health and Human Services →- Sub-agency
- Office of Assistant Secretary for Preparedness and Response
- Office
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Funding agency
- Department of Health and Human Services
- Funding office
- BARDA - ASPR / DAAPPO / BARDA DCMA
See every contract Amgen USA INC has won
Full contracting history, year-over-year trends, subaward graph, and recompete alerts.
View Amgen USA INC profile →